The Pathology Core enables City of Hope Cancer Center investigators to directly study the DNA, RNA and protein in human tumors to validate specific hypotheses generated from pre-clinical studies. It also provides analyses of specific protein expression in tumor tissues to enable scientists to discern the distribution patterns of these proteins in specific cell types. The Pathology Core provides services primarily in the areas of expertise of the members of the Department of Anatomic Pathology. They fall into the following areas: (1) performance and assistance in the routine histological processing of tissues, including paraffin embedding, sectioning, and hematoxylin and eosin (H&E) staining of human tissue, animal tissue, and preparations from cell lines, as well as specialized histological services such as preparation of multi-tumor blocks or tissue arrays to the specifications o1 the researchers;(2) performance and interpretation of immunohistochemistry for the detection of cell products in normal and disease states, including evaluation and technical development of new antibodies as well as the technology to detect multiple antigens in the same histological section;(3) performance and assistance in Laser Capture Microdissection from paraffin or frozen sections to obtain enrichment of specific cell types, including isolation of malignant cells, for the analysis of proteins, RNA and/or DNA content;(4) performance and assistance in preparing formalin-fixed tissues for conventional PCR including RT-PCR;and (5) consultation services to Cancer Center investigators. Expertise in the pathological basis of disease, the histological manifestations of disease, and the use of human tissues for studying disease states is available for the preparation of grants and papers and in the design of experiments. During the prior 12 month reporting period, the Pathology Core provided service to 33 Cancer Center members from all five Research Programs and one non-aligned member. Peer-reviewed usage accounted for 69% of usage during this same reporting period. The proposed annual budget for the core is $406,308, with 28% from the institution, 32% from user fees, and 40% ($160,982) requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-28
Application #
8208796
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
28
Fiscal Year
2011
Total Cost
$204,795
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Mendez-Dorantes, Carlos; Bhargava, Ragini; Stark, Jeremy M (2018) Repeat-mediated deletions can be induced by a chromosomal break far from a repeat, but multiple pathways suppress such rearrangements. Genes Dev 32:524-536
Bzymek, Krzysztof P; Puckett, James W; Zer, Cindy et al. (2018) Mechanically interlocked functionalization of monoclonal antibodies. Nat Commun 9:1580
Nguyen, Huong Q; Ruel, Nora; Macias, Mayra et al. (2018) Translation and Evaluation of a Lung Cancer, Palliative Care Intervention for Community Practice. J Pain Symptom Manage 56:709-718
Satheesan, Sangeetha; Li, Haitang; Burnett, John C et al. (2018) HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. J Virol 92:
Zhang, Jing; He, Zhiheng; Sen, Subha et al. (2018) TCF-1 Inhibits IL-17 Gene Expression To Restrain Th17 Immunity in a Stage-Specific Manner. J Immunol 200:3397-3406
Sun, Jie; He, Xin; Zhu, Yinghui et al. (2018) SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. Cell Stem Cell 23:355-369.e9
Miao, Yifei; Ajami, Nassim E; Huang, Tse-Shun et al. (2018) Enhancer-associated long non-coding RNA LEENE regulates endothelial nitric oxide synthase and endothelial function. Nat Commun 9:292
Sen, Subha; Wang, Fei; Zhang, Jing et al. (2018) SRC1 promotes Th17 differentiation by overriding Foxp3 suppression to stimulate ROR?t activity in a PKC-?-dependent manner. Proc Natl Acad Sci U S A 115:E458-E467
Murad, John P; Kozlowska, Anna K; Lee, Hee Jun et al. (2018) Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front Immunol 9:2268
Brown, Christine E; Aguilar, Brenda; Starr, Renate et al. (2018) Optimization of IL13R?2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Mol Ther 26:31-44

Showing the most recent 10 out of 1396 publications